Teva Pharmaceutical Industries (NYSE:TEVA) Stock Rating Lowered by StockNews.com

Teva Pharmaceutical Industries (NYSE:TEVA) was downgraded by investment analysts at StockNews.com from a “buy” rating to a “hold” rating in a report released on Thursday.

A number of other equities analysts have also recently issued reports on TEVA. UBS Group dropped their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research note on Thursday, January 30th. Bank of America dropped their target price on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating on the stock in a research note on Thursday, March 6th. Barclays reduced their price target on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research report on Thursday, January 30th. Finally, Piper Sandler boosted their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a report on Friday, January 17th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $23.43.

Teva Pharmaceutical Industries Price Performance

TEVA stock opened at $15.06 on Thursday. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. The firm has a 50 day moving average price of $17.21 and a 200-day moving average price of $18.12. Teva Pharmaceutical Industries has a 52-week low of $12.51 and a 52-week high of $22.80. The firm has a market capitalization of $17.07 billion, a price-to-earnings ratio of -10.38, a PEG ratio of 1.44 and a beta of 0.82.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Equities research analysts forecast that Teva Pharmaceutical Industries will post 2.5 EPS for the current fiscal year.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. FMR LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 30.7% during the 4th quarter. FMR LLC now owns 81,983,231 shares of the company’s stock valued at $1,806,910,000 after buying an additional 19,242,468 shares during the period. Clal Insurance Enterprises Holdings Ltd lifted its holdings in Teva Pharmaceutical Industries by 12.8% in the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company’s stock valued at $859,935,000 after acquiring an additional 4,418,961 shares during the period. Ion Asset Management Ltd. lifted its holdings in Teva Pharmaceutical Industries by 1.1% in the fourth quarter. Ion Asset Management Ltd. now owns 36,650,000 shares of the company’s stock valued at $807,766,000 after acquiring an additional 409,778 shares during the period. Lingotto Investment Management LLP boosted its position in Teva Pharmaceutical Industries by 2.6% in the fourth quarter. Lingotto Investment Management LLP now owns 27,192,388 shares of the company’s stock worth $599,320,000 after purchasing an additional 688,862 shares during the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. grew its stake in shares of Teva Pharmaceutical Industries by 2.2% during the 4th quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,035,422 shares of the company’s stock valued at $573,822,000 after purchasing an additional 569,412 shares during the period. Hedge funds and other institutional investors own 54.05% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.